PT  - JOURNAL ARTICLE
AU  - Silangcruz, Krixie
AU  - Nishimura, Yoshito
AU  - Czech, Torrey
AU  - Kimura, Nobuhiko
AU  - Yess, James
TI  - Procalcitonin to Predict Severity of Acute Cholangitis and Need for Urgent Biliary Decompression: Systematic Scoping Review
AID  - 10.1101/2021.08.24.21262522
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.24.21262522
4099  - http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262522.short
4100  - http://medrxiv.org/content/early/2021/08/26/2021.08.24.21262522.full
AB  - Background Serum Procalcitonin (PCT) has been reported as a potential biomarker to predict the severity of acute cholangitis (AC) or the need for urgent biliary decompression. This study aimed to identify and summarize the existing research about the serum PCT and the severity of AC, and to find gaps where future studies can be targeted towards.Methods Following the PRISMA Extension for Scoping Reviews, MEDLINE, EMBASE, and Google Scholar were searched for all peer-reviewed articles with relevant keywords including “cholangitis” and “procalcitonin” from their inception to July 13, 2021.Results We identified six studies. All the studies employed case-control design and aimed to evaluate the usefulness of serum PCT to predict the severity of AC with key identified outcomes. While potential cut-off values of serum PCT for severe AC ranged from 1.8–3.1 ng/mL, studies used different severity criteria and the definition of urgent biliary decompression. No studies proposed cut-off PCT values for the need for urgent biliary decompression.Conclusion This scoping review identified that the current level of evidence regarding the usefulness of serum PCT in assessing the severity of AC. Further clinical research is warranted with a focus on standardized outcome measures employing prospective or experimental designs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request from the authors.